MK-0524: Clinical Trials

4 trials of MK-0524, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 24Completed 4

Follow MK-0524: new trials by email Literature Review of MK-0524 trials Research Report on MK-0524

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
niacin (+) laropiprant, Comparator: placebo (unspecified) - Dyslipidemia
Phase 2CompletedMerck Sharp & Dohme LLC5752005-06-012017-02-17
MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)
Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks, Comparator : niacin / Duraton of Treatment: 4 Weeks - Hypercholesterolemia
Phase 2CompletedMerck Sharp & Dohme LLC4072005-04-012017-04-07
MK0524A Phase IIb Study (0524A-011)(COMPLETED)
Comparator: niacin / Duration of Treatment: 17 Weeks, MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks, Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks - Flushing
Phase 2CompletedMerck Sharp & Dohme LLC1542004-08-012015-08-25
MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)
MK0524 - Seasonal Allergies
Phase 2CompletedMerck Sharp & Dohme LLC7662003-07-012015-12-22

Conditions studied

Dyslipidemias (1)  ·  Flushing (1)  ·  Hypercholesterolemia (1)  ·  Rhinitis, Allergic, Seasonal (1)

Sponsors

Merck Sharp & Dohme LLC (4)

Results publications

PMID 17392721, PMID 19748656